Nifty
:
25910.05
Sensex
:
84562.78
30.90 (0.12%)
84.11 (0.10%)
Nifty
Sensex
:
:
25910.05
84562.78
30.90 (0.12%)
84.11 (0.10%)

Alkem Laboratories Ltd.

Pharmaceuticals & Drugs - Domestic

Rating :
70/99

BSE: 539523 | NSE: ALKEM

NSE BSE
5722.50
14-Nov-2025
  • Open
  • High
  • Low
  • Previous Close
  •  5800.5
  •  5808.5
  •  5607.5
  •  5725.50
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  383633
  •  2185409713
  •  5868
  •  4491.65

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 68,446.18
  • 28.99
  • 2
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 68,860.61
  • 0.79%
  • 5.13

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 51.20%
  • 0.08%
  • 17.18%
  • FII
  • DII
  • Others
  • 9.47%
  • 20.56%
  • 1.51%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 10.16
  • 7.90
  • 3.78

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 11.40
  • 5.28
  • 9.31

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 11.31
  • 6.45
  • 30.08

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 29.33
  • 28.91
  • 34.78

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 4.89
  • 5.06
  • 5.21

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 20.36
  • 20.61
  • 22.23

Earnings Forecasts:

(Updated: 08-11-2025)
Description
2024
2025
2026
2027
Adj EPS
181.11
199.99
190.45
217.9
P/E Ratio
31.60
28.61
30.05
26.26
Revenue
12804.6
14250.1
15600.4
17096.7
EBITDA
2512.15
2866.94
3254.57
3687.37
Net Income
2165.48
2396.4
2295.41
2660
ROA
13.02
13.71
12.67
14.1
P/B Ratio
5.71
4.96
4.41
3.90
ROE
19.42
18.51
15.54
15.92
FCFF
1504.49
1640.14
1686.01
1986.1
FCFF Yield
2.3
2.5
2.57
3.03
Net Debt
-1084.44
-2843.17
-4167.99
-5647.52
BVPS
1002.37
1154.49
1296.48
1468.03

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Sep 25
Sep 24
Var%
Jun 25
Jun 24
Var%
Mar 25
Mar 24
Var%
Dec 24
Dec 23
Var%
Net Sales
4,000.99
3,414.67
17.17%
3,371.14
3,031.82
11.19%
3,143.75
2,935.82
7.08%
3,374.28
3,323.87
1.52%
Expenses
3,080.22
2,661.84
15.72%
2,632.09
2,423.18
8.62%
2,752.46
2,533.84
8.63%
2,614.89
2,616.28
-0.05%
EBITDA
920.77
752.83
22.31%
739.05
608.64
21.43%
391.29
401.98
-2.66%
759.39
707.59
7.32%
EBIDTM
23.01%
22.05%
21.92%
20.08%
12.45%
13.69%
22.51%
21.29%
Other Income
103.69
134.48
-22.90%
136.49
120.31
13.45%
145.96
88.17
65.54%
92.99
93.64
-0.69%
Interest
35.02
28.14
24.45%
29.78
29.11
2.30%
28.42
26.86
5.81%
36.03
25.46
41.52%
Depreciation
93.61
78.91
18.63%
87.68
80.48
8.95%
112.49
83.43
34.83%
85.28
69.56
22.60%
PBT
895.83
780.26
14.81%
771.01
619.36
24.48%
396.34
367.34
7.89%
731.07
654.90
11.63%
Tax
116.23
78.30
48.44%
102.69
69.12
48.57%
73.33
62.86
16.66%
90.28
50.62
78.35%
PAT
779.60
701.96
11.06%
668.32
550.24
21.46%
323.01
304.48
6.09%
640.79
604.28
6.04%
PATM
19.49%
20.56%
19.82%
18.15%
10.27%
10.37%
18.99%
18.18%
EPS
63.99
57.60
11.09%
55.56
45.60
21.84%
25.58
24.56
4.15%
52.35
49.77
5.18%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Net Sales
13,890.16
12,964.52
12,667.58
11,599.26
10,634.19
8,865.01
8,344.36
7,357.19
6,391.84
5,687.53
4,924.84
Net Sales Growth
9.32%
2.34%
9.21%
9.08%
19.96%
6.24%
13.42%
15.10%
12.38%
15.49%
 
Cost Of Goods Sold
5,055.80
4,121.25
4,327.06
4,381.43
3,565.78
3,124.81
2,959.14
2,586.30
1,986.45
1,807.71
1,630.87
Gross Profit
8,834.36
8,843.27
8,340.52
7,217.83
7,068.41
5,740.20
5,385.22
4,770.89
4,405.39
3,879.82
3,293.97
GP Margin
63.60%
68.21%
65.84%
62.23%
66.47%
64.75%
64.54%
64.85%
68.92%
68.22%
66.88%
Total Expenditure
11,079.66
10,452.37
10,422.09
9,989.81
8,581.27
6,922.62
6,870.97
6,242.42
5,382.92
4,688.58
4,071.59
Power & Fuel Cost
-
168.99
162.58
163.94
162.96
129.95
130.14
121.48
112.64
86.34
66.33
% Of Sales
-
1.30%
1.28%
1.41%
1.53%
1.47%
1.56%
1.65%
1.76%
1.52%
1.35%
Employee Cost
-
2,453.92
2,201.01
2,131.35
1,962.71
1,621.03
1,505.49
1,362.46
1,191.64
1,003.85
861.08
% Of Sales
-
18.93%
17.38%
18.37%
18.46%
18.29%
18.04%
18.52%
18.64%
17.65%
17.48%
Manufacturing Exp.
-
1,282.95
1,183.76
972.37
1,092.63
748.03
765.43
806.17
838.87
692.26
550.16
% Of Sales
-
9.90%
9.34%
8.38%
10.27%
8.44%
9.17%
10.96%
13.12%
12.17%
11.17%
General & Admin Exp.
-
850.62
833.21
819.84
641.25
506.77
525.62
512.52
469.90
379.78
334.28
% Of Sales
-
6.56%
6.58%
7.07%
6.03%
5.72%
6.30%
6.97%
7.35%
6.68%
6.79%
Selling & Distn. Exp.
-
1,319.76
1,307.60
1,339.88
1,070.10
700.98
854.48
726.21
675.43
596.44
503.69
% Of Sales
-
10.18%
10.32%
11.55%
10.06%
7.91%
10.24%
9.87%
10.57%
10.49%
10.23%
Miscellaneous Exp.
-
254.88
406.87
181.00
85.84
91.05
130.67
127.28
107.99
122.20
503.69
% Of Sales
-
1.97%
3.21%
1.56%
0.81%
1.03%
1.57%
1.73%
1.69%
2.15%
2.54%
EBITDA
2,810.50
2,512.15
2,245.49
1,609.45
2,052.92
1,942.39
1,473.39
1,114.77
1,008.92
998.95
853.25
EBITDA Margin
20.23%
19.38%
17.73%
13.88%
19.30%
21.91%
17.66%
15.15%
15.78%
17.56%
17.33%
Other Income
479.13
493.74
310.84
216.08
162.65
233.21
104.22
87.70
115.42
112.01
239.71
Interest
129.25
121.70
112.41
107.36
52.37
58.92
65.06
54.63
55.33
45.16
71.24
Depreciation
379.06
357.16
299.30
310.42
303.96
274.58
252.76
193.18
143.03
101.17
93.31
PBT
2,794.25
2,527.03
2,144.62
1,407.75
1,859.24
1,842.10
1,259.79
954.66
925.98
964.63
928.41
Tax
382.53
311.03
211.67
297.96
163.96
224.33
110.48
181.02
287.56
59.96
176.18
Tax Rate
13.69%
12.31%
10.46%
22.84%
8.89%
12.18%
8.77%
18.96%
31.05%
6.22%
18.98%
PAT
2,411.72
2,166.10
1,795.77
984.17
1,645.62
1,585.02
1,127.07
760.51
630.94
892.03
741.59
PAT before Minority Interest
2,362.52
2,216.00
1,811.46
1,006.81
1,680.32
1,617.77
1,149.31
773.64
638.42
904.67
752.23
Minority Interest
-49.20
-49.90
-15.69
-22.64
-34.70
-32.75
-22.24
-13.13
-7.48
-12.64
-10.64
PAT Margin
17.36%
16.71%
14.18%
8.48%
15.47%
17.88%
13.51%
10.34%
9.87%
15.68%
15.06%
PAT Growth
11.60%
20.62%
82.47%
-40.19%
3.82%
40.63%
48.20%
20.54%
-29.27%
20.29%
 
EPS
201.65
181.11
150.15
82.29
137.59
132.53
94.24
63.59
52.75
74.58
62.01

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Shareholder's Funds
11,984.87
10,312.06
9,045.29
8,637.90
7,376.73
6,160.67
5,439.34
4,863.77
4,467.64
3,691.96
Share Capital
23.91
23.91
23.91
23.91
23.91
23.91
23.91
23.91
23.91
23.91
Total Reserves
11,924.81
10,268.61
9,020.78
8,613.39
7,351.70
6,135.40
5,413.93
4,838.87
4,443.34
3,668.03
Non-Current Liabilities
-445.76
-648.88
-688.00
-892.74
-750.71
-540.58
-288.92
-358.61
-400.78
-306.15
Secured Loans
62.42
40.00
0.00
0.03
18.47
63.60
219.80
122.12
175.01
112.49
Unsecured Loans
248.49
0.00
0.00
9.35
9.46
10.31
11.50
8.61
6.55
10.97
Long Term Provisions
338.22
299.86
369.36
332.75
250.73
222.98
173.72
150.27
102.17
82.96
Current Liabilities
3,958.69
3,994.55
3,707.15
4,805.34
3,604.05
3,244.58
2,217.53
2,383.31
1,689.69
1,537.60
Trade Payables
1,839.35
1,748.12
1,165.03
1,173.38
1,069.41
954.05
962.25
960.71
741.37
580.48
Other Current Liabilities
1,164.24
891.94
838.81
771.42
643.11
555.47
428.08
520.04
339.25
366.01
Short Term Borrowings
734.89
1,172.63
1,307.12
2,570.62
1,635.96
1,503.51
671.27
761.27
472.37
464.17
Short Term Provisions
220.21
181.86
396.19
289.92
255.57
231.55
155.93
141.29
136.70
126.94
Total Liabilities
15,946.56
14,060.07
12,454.15
12,759.93
10,411.35
9,012.97
7,500.56
7,010.02
5,871.78
5,018.43
Net Block
2,852.31
2,872.78
2,682.85
2,901.73
2,792.98
2,908.01
2,530.44
2,283.59
1,797.04
1,449.54
Gross Block
4,719.78
4,543.69
4,050.24
4,185.64
3,768.89
3,606.95
3,026.08
2,603.78
1,977.20
1,538.64
Accumulated Depreciation
1,867.47
1,670.91
1,367.39
1,283.91
975.91
698.94
495.64
320.19
180.16
89.10
Non Current Assets
5,007.03
3,648.49
3,724.47
4,324.50
3,482.53
3,507.32
3,284.43
2,996.80
2,954.64
2,249.73
Capital Work in Progress
548.07
158.57
323.24
339.48
393.28
362.97
492.96
380.97
299.26
172.42
Non Current Investment
943.24
334.80
304.61
231.67
153.95
91.50
95.74
98.45
259.44
234.39
Long Term Loans & Adv.
508.16
203.74
139.07
154.44
93.77
98.16
118.64
141.37
193.07
142.35
Other Non Current Assets
155.25
78.60
274.70
697.18
48.55
46.68
46.65
92.42
405.83
251.03
Current Assets
10,811.19
10,411.58
8,606.42
8,433.70
6,928.82
5,505.65
4,216.13
4,013.22
2,917.14
2,768.70
Current Investments
902.26
148.99
317.21
139.31
178.83
169.89
227.88
345.82
293.56
274.18
Inventories
2,922.41
2,661.18
2,607.53
3,005.53
2,312.44
1,818.82
1,499.87
1,442.19
1,206.00
909.37
Sundry Debtors
2,466.25
2,252.81
2,132.18
1,884.60
1,607.21
1,649.36
1,248.41
1,080.50
713.64
567.51
Cash & Bank
1,563.08
1,579.35
2,616.89
2,578.58
1,990.45
1,092.21
661.60
576.78
399.26
780.90
Other Current Assets
2,957.19
237.13
244.68
239.80
839.89
775.37
578.37
567.93
304.68
236.74
Short Term Loans & Adv.
2,800.91
3,532.12
687.93
585.88
504.70
482.24
405.00
390.63
171.35
141.30
Net Current Assets
6,852.50
6,417.03
4,899.27
3,628.36
3,324.77
2,261.07
1,998.60
1,629.91
1,227.45
1,231.10
Total Assets
15,818.22
14,060.07
12,330.89
12,758.20
10,411.35
9,012.97
7,500.56
7,010.02
5,871.78
5,018.43

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Cash From Operating Activity
1,912.84
1,948.07
1,682.50
1,111.02
1,264.90
585.08
779.65
266.04
471.14
725.83
PBT
2,527.03
2,023.13
1,304.77
1,844.28
1,842.10
1,259.79
954.66
925.98
964.63
928.41
Adjustment
103.80
383.57
324.35
208.60
164.64
255.87
216.37
116.47
33.02
-14.42
Changes in Working Capital
-213.97
-51.69
326.77
-544.96
-341.16
-647.20
-140.27
-573.24
-262.55
10.05
Cash after chg. in Working capital
2,416.86
2,355.01
1,955.89
1,507.92
1,665.58
868.46
1,030.76
469.21
735.10
924.04
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-504.02
-406.94
-273.39
-396.90
-400.68
-283.38
-251.11
-203.17
-263.96
-198.21
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-1,298.76
-1,008.50
112.84
-1,435.13
-998.54
-741.35
-316.39
-357.23
-285.93
202.27
Net Fixed Assets
75.19
-74.10
-101.58
-254.26
-139.76
-310.63
-342.15
-531.27
-390.07
160.79
Net Investments
-1,577.80
176.57
-476.94
-376.23
-196.34
-260.44
-151.10
-26.86
-359.97
-87.11
Others
203.85
-1,110.97
691.36
-804.64
-662.44
-170.28
176.86
200.90
464.11
128.59
Cash from Financing Activity
-810.99
-1,145.01
-1,760.82
379.57
-271.75
79.15
-378.94
84.56
-137.88
-927.27
Net Cash Inflow / Outflow
-196.91
-205.44
34.52
55.46
-5.39
-77.12
84.32
-6.63
47.33
0.83
Opening Cash & Equivalents
66.31
273.80
232.18
174.22
175.94
249.05
166.71
166.63
127.03
123.75
Closing Cash & Equivalent
-120.09
66.31
273.80
232.18
174.22
175.94
249.05
166.71
166.63
127.05

Financial Ratios

Consolidated /

Standalone
Description
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Book Value (Rs.)
999.47
860.94
756.56
722.48
616.95
515.21
454.86
406.76
373.67
308.82
ROA
14.77%
13.66%
7.99%
14.50%
16.66%
13.92%
10.66%
9.91%
16.61%
14.59%
ROE
19.93%
18.74%
11.39%
20.99%
23.91%
19.82%
15.02%
13.69%
22.18%
22.47%
ROCE
21.56%
19.52%
13.09%
18.69%
22.56%
18.71%
16.49%
17.86%
21.31%
23.09%
Fixed Asset Turnover
4.17
4.51
4.36
3.84
3.56
3.74
3.80
3.75
3.33
3.07
Receivable days
44.62
41.28
40.86
41.72
45.33
42.66
39.69
38.15
39.95
39.57
Inventory Days
52.79
49.60
57.10
63.54
57.51
48.86
50.14
56.31
65.96
61.23
Payable days
158.86
122.87
97.40
114.79
118.18
52.05
60.17
61.04
52.36
49.96
Cash Conversion Cycle
-61.46
-31.98
0.57
-9.53
-15.34
39.47
29.66
33.42
53.55
50.84
Total Debt/Equity
0.09
0.12
0.14
0.30
0.23
0.26
0.17
0.21
0.15
0.18
Interest Cover
21.76
19.00
13.15
36.22
32.26
20.36
18.48
17.74
22.36
14.03

Annual Reports:

FY 2025
FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
FY 2019
FY 2018
FY 2017
FY 2016

News Update:


  • Alkem Laboratories - Quarterly Results
    14th Nov 2025, 00:00 AM

    Read More
  • Alkem Laboratories completes EU GMP inspection at Baddi manufacturing facility
    11th Nov 2025, 12:39 PM

    The said inspection was concluded on November 10, 2025 with no critical or major observations

    Read More
  • Alkem Laboratories launches 'Pertuza' injection
    22nd Sep 2025, 16:58 PM

    Alkem’s Pertuza is an affordable, indigenously-developed and manufactured biosimilar of pertuzumab

    Read More
  • Alkem Laboratories launches Olesoft Trucera moisturizing lotion
    19th Aug 2025, 15:00 PM

    The company already has a strong presence in the moisturizer segment with its Olesoft range of products

    Read More
  • Alkem Laboratories to incorporate subsidiary company in Kingdom of Saudi Arabia
    12th Aug 2025, 15:48 PM

    Pursuant to incorporation of such subsidiary, the company will hold 51% of the total share capital

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.